Literature DB >> 15201266

Long term survival in primary pulmonary hypertension.

M Halank1, C Marx, G Hoeffken.   

Abstract

The mean survival of patients with severe primary pulmonary hypertension (PPH) is < 3 years without appropriate treatment. There are no long term reports on the spontaneous course of mild PPH over a longer period. Stable long term follow up is described of a 39 year old patient with PPH without treatment over a 30 year period. PPH had been diagnosed 30 years previously after right heart catheterisation (mean pulmonary artery pressure 35 mm Hg) and 30 years later, repeated measurements showed nearly unchanged haemodynamic parameters. Further examinations confirmed the diagnosis of PPH. It is suggested that PPH with modestly limited physical activity (New York Heart Association functional class II) does not always seem to coincide with progression of the disease and, therefore, it may be feasible to withhold treatment while closely monitoring these patients.

Entities:  

Mesh:

Year:  2004        PMID: 15201266      PMCID: PMC1768340          DOI: 10.1136/hrt.2004.035725

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.

Authors:  Horst Olschewski; Beate Rohde; Jürgen Behr; Ralph Ewert; Tobias Gessler; H Ardeschir Ghofrani; Thomas Schmehl
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

2.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

3.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Authors:  R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin
Journal:  Lancet       Date:  2001-10-06       Impact factor: 79.321

4.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiéry; Carmine Dario Vizza; Meinhard Kneussl; Alessandra Manes; Olivier Sitbon; Adam Torbicki; Marion Delcroix; Robert Naeije; Marius Hoeper; Ari Chaouat; Sophie Morand; Bruno Besse; Gerald Simonneau
Journal:  J Am Coll Cardiol       Date:  2002-05-01       Impact factor: 24.094

5.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors:  Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

6.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

8.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

9.  Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension.

Authors:  M M Hoeper; E Spiekerkoetter; V Westerkamp; R Gatzke; H Fabel
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

  10 in total
  2 in total

Review 1.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

2.  Long-term survival in idiopathic pulmonary arterial hypertension associated with massive pulmonary artery dilation.

Authors:  Vanja Petrovic; Christopher J Ryerson; Robert D Levy
Journal:  Can Respir J       Date:  2011 May-Jun       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.